Cargando…

Genetic Variation in miR-27a Is Associated with Fluoropyrimidine-Associated Toxicity in Patients with Dihydropyrimidine Dehydrogenase Variants after Genotype-Guided Dose Reduction

Dihydropyrimidine dehydrogenase (DPYD) is the rate-limiting enzyme involved in the metabolism of fluoropyrimidine-based chemotherapy. However, single-nucleotide variants (SNVs) in DPYD only partially explain fluoropyrimidine-induced toxicity. The expression of DPYD has previously been shown to be re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Medwid, Samantha, Wigle, Theodore J., Ross, Cameron, Kim, Richard B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487873/ https://www.ncbi.nlm.nih.gov/pubmed/37686089 http://dx.doi.org/10.3390/ijms241713284

Ejemplares similares

Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events
por: Wigle, Theodore J., et al.
Publicado: (2021)

DPYD Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation
por: Wigle, Theodore J., et al.
Publicado: (2023)

Poor association between dihydropyrimidine dehydrogenase ( DPYD ) genotype and fluoropyrimidine‐induced toxicity in an Asian population
por: Kanai, Masashi, et al.
Publicado: (2022)

Strong Association of a Common Dihydropyrimidine Dehydrogenase Gene Polymorphism with Fluoropyrimidine-Related Toxicity in Cancer Patients
por: Gross, Eva, et al.
Publicado: (2008)

Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients
por: Del Re, Marzia, et al.
Publicado: (2015)

Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?
por: Del Re, Marzia, et al.
Publicado: (2010)

Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase
por: Merloni, Filippo, et al.
Publicado: (2019)

In Vitro Assessment of Fluoropyrimidine-Metabolizing Enzymes: Dihydropyrimidine Dehydrogenase, Dihydropyrimidinase, and β-Ureidopropionase
por: Hishinuma, Eiji, et al.
Publicado: (2020)

The Role of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms in Fluoropyrimidine-Based Cancer Chemotherapy in an Iranian Population
por: Abbasian, Mohammad Hadi, et al.
Publicado: (2020)

Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study
por: Soria-Chacartegui, Paula, et al.
Publicado: (2021)

Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
por: Milano, G, et al.
Publicado: (1999)

Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients
por: Ruzzo, A, et al.
Publicado: (2017)

The Evaluation of Dihydropyrimidine Dehydrogenase Enzyme Level in the Serum of Colorectal Cancer Iraqi Males on Fluoropyrimidine-Based Chemotherapy (Capecitabine)
por: Challoob, Muhtada A, et al.
Publicado: (2023)

Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase-inhibitory fluoropyrimidine in EGFR-mutated lung adenocarcinoma: Retrospective and in vitro studies
por: IZUMI, HIROKI, et al.
Publicado: (2015)

Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase
por: Falvella, Felicia Stefania, et al.
Publicado: (2015)

Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer
por: Ichikawa, W, et al.
Publicado: (2003)

Rare Dihydropyrimidine Dehydrogenase Variants and Toxicity by Floropyrimidines: A Case Report
por: Palmirotta, Raffaele, et al.
Publicado: (2019)

Dihydropyrimidine dehydrogenase deficiency as a cause of fatal 5-Fluorouracil toxicity
por: Fidai, Shiraz S., et al.
Publicado: (2018)

A Case of Hyperammonemia Associated with High Dihydropyrimidine Dehydrogenase Activity
por: Nagaharu, Keiki, et al.
Publicado: (2016)

Concordance of Blood-Based and Normal Tissue-Based Dihydropyrimidine Dehydrogenase (DPYD) Genotyping
por: Morelli, Cristina, et al.
Publicado: (2022)

Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen?
por: Vogel, Wendy H., et al.
Publicado: (2020)

Revisiting the Clinical Importance of DPYD*9A (c.85T>C) Variant of Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients Treated with Fluoropyrimidine-Based Chemotherapy
por: Patel, Girijesh Kumar, et al.
Publicado: (2018)

Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours.
por: McLeod, H. L., et al.
Publicado: (1998)

Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.
por: Ridge, S. A., et al.
Publicado: (1998)

Dihydropyrimidine dehydrogenase (DPD) polymorphisms knocking on the door
por: Donadio, Mauro Daniel Spina, et al.
Publicado: (2022)

Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe
por: de With, M., et al.
Publicado: (2023)

Unpredicted Severe Toxicity after 5-Fluorouracil Treatment due to Dihydropyrimidine Dehydrogenase Deficiency
por: Baek, Jin Ho, et al.
Publicado: (2006)

DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview
por: Paulsen, Niels Herluf, et al.
Publicado: (2022)

Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression
por: Jensen, Søren A, et al.
Publicado: (2009)

Plasma concentrations of 5-fluorouracil and F-β-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil
por: Yamada, Y, et al.
Publicado: (2003)

Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer
por: Horiguchi, J, et al.
Publicado: (2002)

A ferredoxin-dependent dihydropyrimidine dehydrogenase in Clostridium chromiireducens
por: Wang, Feifei, et al.
Publicado: (2020)

Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase
por: Kang, Jihyun, et al.
Publicado: (2021)

Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping
por: Royer, B., et al.
Publicado: (2023)

A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening
por: Tong, Chi C., et al.
Publicado: (2018)

Upfront DPYD Genotyping and Toxicity Associated with Fluoropyrimidine-Based Concurrent Chemoradiotherapy for Oropharyngeal Carcinomas: A Work in Progress
por: Desilets, Antoine, et al.
Publicado: (2022)

Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy
por: Diasio, Robert B., et al.
Publicado: (2022)

A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency
por: Pallet, Nicolas, et al.
Publicado: (2020)

Dihydropyrimidine dehydrogenase deficiency in patients with severe toxicity after 5-fluorouracil: a retrospective single-center study
por: Detailleur, Stephanie, et al.
Publicado: (2021)

Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity
por: Ockeloen, Charlotte W, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jdv9ioa4cu8b5j2rmt4qmmasqs